Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Is the GLP-1 Receptor Agonist Semaglutide Able to Alleviate Mood in Patients With Major Depressive Disorder and Overweight or Obesity

NCT07136714 is registered in ClinicalTrials.gov with Nordsjaellands Hospital as lead sponsor.

NCT NCT07136714
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07136714 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Is the GLP-1 Receptor Agonist Semaglutide Able to Alleviate Mood in Patients With Major Depressive Disorder and Overweight or Obesity
Lead sponsor
Nordsjaellands Hospital
Phase
Phase 4
Overall status
Recruiting
Start date
September 11, 2025
Completion date
September 30, 2027
Enrollment
116 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

major depressive disorder